Uncommon Indications for Extracorporeal Toxin Removal (ECTR) Robert S. Hoffman, MD Director, Division of Medical Toxicology NYU School of Medicine

Size: px
Start display at page:

Download "Uncommon Indications for Extracorporeal Toxin Removal (ECTR) Robert S. Hoffman, MD Director, Division of Medical Toxicology NYU School of Medicine"

Transcription

1 Uncommon Indications for Extracorporeal Toxin Removal (ECTR) Robert S. Hoffman, MD Director, Division of Medical Toxicology NYU School of Medicine

2 Disclosure I have no financial or academic conflicts of interest to report I will NOT be discussing toxins either currently reviewed or anticipated to be reviewed by the EXTRIP Workgroup

3 Objectives Fundamental principles of ECTR Assessment of ECTR Does it work Application of principles to real scenarios

4 Principles of ECTR

5 3 Toxin Specific Governing Principles Molecular weight Volume of distribution Protein binding

6 Molecular weight The size of the molecule must be small enough to fit through the pores of the filter Volume of distribution Protein binding

7 Volume of distribution Only the blood compartment gets filtered 0.08 L/kg A traditionally small Vd = 1 L/kg or less Utility may improve for toxins with a large Vd if ECTR is performed before distribution Molecular weight Protein binding

8 Protein binding As protein binding increases available free toxin decreases Pharmacokinetic parameters are often misleading Consider salicylates of valproate Molecular weight Volume of distribution

9 4 th Principle Clearance ECTR must improve on endogenous clearance Problem: Published data for clearance rarely apply to the patient in front of you.

10 Seminars in Dialysis 2014:27:362

11 ECTR Conditions Max CL (ml/min) ET 1L whole blood exchanged/hour, HCT = 40% 10 PD TPE CRRT IHD/HF/ HP 2L exchange every hour, 50% equilibration of dialysate compared to plasma QB = 140 ml/min and a plasma removal rate 50 ml/min QB = 180 ml/min, high volume CRRT (effluent flow = 45 ml/hr/kg), weight = 70 kg QB = 400 ml/min, HCT = 40%, ER = 100%

12 Assessing ECTR Terminology Efficiency Effectiveness Cost effectiveness Outcome Is the toxin removed Does removal equate with improved outcome Is the outcome worth the risks, benefits and costs

13 Case In error, a patient receives and intravenous overdose of a toxin known to be associated with delayed, debilitating, and long-term consequences Absorption is complete The event is recognized quickly There are no cases of intravenous overdose of this toxin ever reported in any language There is no known antidote

14 Case (continued) The toxin has a low molecular weight Protein binding and volume of distribution are unknown But assumed to be small by analogy No data are available regarding Endogenous clearance or Clearance during hemodialysis

15 Case (cont) A decision is made to attempt hemodialysis: The consequences of the overdose are assumed to be severe There is no alternative therapy The patient has no contraindications to the procedure The patient undergoes hemodialysis without complications and remains asymptomatic

16 Did Hemodialysis Benefit The Patient?

17 Concentration Time

18 Concentration Comparison of Ins and Outs Time

19 A Mathematical Interlude [ ] Into HD [ ] Out of HD ER % Clearance (ml/min) ER = Extraction ratio = C in -C out C in

20 Why Did Extraction Fall Over Time?? Saturable Protein Binding?

21 How Can We Be Sure What We Did?

22 Measure Dialysate Time (hours) Dialysate Concentration (mcg/l) Dialysate flow constant at 700 ml/min

23 Dialysate [ ] Time

24 Concentration Time

25 Total Collected in Dialysate Integrate the area under the curve of the dialysate concentration vs time graph Total 1.0 mg Less than 1% of the administered dose

26 Assessments (1) Apparent half life during ECTR Ignores distribution Ignores endogenous clearance Comparison of apparent half-life before, during and after ECTR Same concerns as above PLUS Apparent half life before ECTR is often prolonged by ongoing absorption

27 Assessments (2) Extraction ratio with calculation to assume clearance Only tells you what the technique is doing Does not account for endogenous clearance Either normal or during ECTR Very misleading for high Vd toxins that are well filtered (such as digoxin)

28 Assessments (3) Gold standard Directly measure the amount of toxin filtered or otherwise removed by the technique Caution This is only the best determination of efficiency and we still have to evaluate effectiveness and even further cost effectiveness

29 Uncommon Indications for ECTR in the Real World

30

31

32 Methylxanthines By Analogy Parameter Theophylline Caffeine Molecular Mass Protein binding Volume of distribution Da 194 Da 50% 35% 0.5 L/kg 0.7 L/kg

33 A 59 year old woman with ESRD on HD develops a headache 2 hours into each dialysis. She drinks 4-6 cups of coffee each day No mention of the number of cups she drinks before or after HD No caffeine concentrations

34

35 50 gram ingestion of caffeine Got very sick Had a very high caffeine concentration 405 mg/l Got many therapies including hemodialysis Got better No clearance data

36 10 month old Ingested 30 x 200mg caffeine pills Caffeine 170 mg/l Seizures, cardiac arrest, aspiration

37

38

39

40

41 2014;53(23): gram ingestion

42

43

44

45 Parameter Amatoxin Facts Result Molecular weights α 990 β 373 γ 994 Protein binding Volume of distribution Clearance Unknown in humans, no binding to albumin in dogs (Faulstich) Unknown in humans; ml/kg in dogs (Faulstich) Approaches creatinine clearance in dogs (Faulstich)

46

47

48

49 Correction of the water-electrolyte imbalance Gastric lavage and continuous drainage of gastroduodenal fluids Cathartics and activated charcoal every hour Enhancement of toxin removal: peritoneal dialysis, plasmapheresis with plasma exchange, and forced diuresis. Most patients were treated with two techniques and some received three. Pharmacologic therapy included high-dose penicillin and thioctic acid

50 53 patients: 25 males, 20 females, Ages ranged from 4 to 72 years The overall mortality in this series was 11.3%; (6/53) Among the survivors, liver injury was absent to mild in 13 patients, moderate in 21, and severe in 13. All deaths were due to acute liver failure and occurred 6 to 12 days after admission. Only one patient experienced severe kidney failure with anuria.

51

52 15 years, 41 patients with Amanita poisoning Treatment consisted of: fluid and electrolyte replacement, oral activated charcoal and lactulose, IV penicillin, combined hemodialysis and hemoperfusion in two 8 hour sessions, some received IV thioctic acid, others IV silibinin, all received a special diet. All patients improved and were discharged from the hospital asymptomatic. We concluded that intensive combined treatment applied is effective

53 Mullins ME, Horowitz ZB: The Futility of Hemoperfusion and Hemodialysis in Amanita phalloides Poisoning. Vet Hum Toxicol 2000 ;42: adults with confirmed Amanita poisoning Treated with hemodialysis immediately (23 h after ingestion) and later with hemoperfusion A series blood samples were taken to determine the clearance of the toxin by each method No amatoxin was detected before treatment, after treatment, or in the HD/HP circuits Neither HD nor HP contributed to the clearance of amatoxin

54 Fluoride Facts Parameter Molecular weight Protein binding Volume of distribution Elimination Result 19 Daltons None 0.6 L/kg Largely kidney; T 1/2 5.5 hours Baselt RC: Disposition of Toxic Drugs and Chemicals in Man

55 YOU CAN DIALYZE FLUORIDE IN!

56 Seminars in Dialysis 2000;13:86 91

57

58 THE AMERICAN JOURNAL OF CARDIOLOGY 1983;51; 901

59 Ann lntem Med. 1994; 121:

60 Pediatrics 1976;58:90 Peritoneal dialysis was ineffective as the total amount of fluoride removed by this procedure was less than 0.2 mg over two days. This was less than 1.5% of the fluoride excreted in the urine during the same period.

61 A patient is described who accidentally ingested a hydrofluoric acid-containing substance and who likely benefited from hemodialysis. His fluoride level post-dialysis was reduced by approximately 70% from a level drawn three hours prior to the initiation of hemodialysis.

62

63

64 Manganese Poster 219

65 MW 169 Daltons Low protein binding in animals Vd<0.5L/kg in animals Bad ingestion Had many poor prognostic indicators Got IHD and Extraction ratio 91.8% Clearance 97.5 ml/min

66 Summary Manganese useless Caffeine good analogy but limited data Amatoxin I wish I knew, but think not Fluoride makes good sense we need more data Glyphosaste I think you can remove the glyposate but have no idea about surfactant

67 A Plea For Better Data, Please 2014 Jul-Aug;27(4):407

Physiology of Blood Purification: Dialysis & Apheresis. Outline. Solute Removal Mechanisms in RRT

Physiology of Blood Purification: Dialysis & Apheresis. Outline. Solute Removal Mechanisms in RRT Physiology of Blood Purification: Dialysis & Apheresis Jordan M. Symons, MD University of Washington School of Medicine Seattle Children s Hospital Outline Physical principles of mass transfer Hemodialysis

More information

Toxicology & ECTR. PYNICU Friday lecture Dec 2, 2016 Dr TY Li / Dr HP Shum

Toxicology & ECTR. PYNICU Friday lecture Dec 2, 2016 Dr TY Li / Dr HP Shum Toxicology & ECTR PYNICU Friday lecture Dec 2, 2016 Dr TY Li / Dr HP Shum Outline History of ECTR in poisoning Outline of method of ECTR Development of EXTRIP RecommendaMons of EXTRIP Treatment pyramid

More information

An Update from EXTRIP

An Update from EXTRIP Extracorporeal Removal in Poisoning An Update from EXTRIP Dr Paul I Dargan Clinical Toxicology Guy s and St Thomas NHS Foundation Trust London, UK Disclosures Expenses (no honorarium) covered by the EXTRIP

More information

Renal Disease and PK/PD. Anjay Rastogi MD PhD Division of Nephrology

Renal Disease and PK/PD. Anjay Rastogi MD PhD Division of Nephrology Renal Disease and PK/PD Anjay Rastogi MD PhD Division of Nephrology Drugs and Kidneys Kidney is one of the major organ of drug elimination from the human body Renal disease and dialysis alters the pharmacokinetics

More information

ANTIBIOTIC DOSE AND DOSE INTERVALS IN RRT and ECMO

ANTIBIOTIC DOSE AND DOSE INTERVALS IN RRT and ECMO ANTIBIOTIC DOSE AND DOSE INTERVALS IN RRT and ECMO Professor Jeffrey Lipman Department of Intensive Care Medicine Royal Brisbane Hospital University of Queensland NO CONFLICT OF INTERESTS Important concept

More information

Rational Dose Prediction. Pharmacology. φαρμακον. What does this mean? pharmakon. Medicine Poison Magic Spell

Rational Dose Prediction. Pharmacology. φαρμακον. What does this mean? pharmakon. Medicine Poison Magic Spell 1 Rational Dose Prediction Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland, New Zealand 2 Pharmacology Pharmacology is derived from a Greek word (pharmakon). The Greeks used

More information

Valproate overdose: what is the role of carnitine?

Valproate overdose: what is the role of carnitine? Valproate overdose: what is the role of carnitine? Ruben Thanacoody National Poisons Information Service (Newcastle) Newcastle upon Tyne Hospitals NHS Trust Medical Toxicology Centre, Newcastle University

More information

Marc Ghannoum, Thomas D. Nolin, Valery Lavergne, and Robert S. Hoffman for the EXTRIP group

Marc Ghannoum, Thomas D. Nolin, Valery Lavergne, and Robert S. Hoffman for the EXTRIP group Marc Ghannoum, Thomas D. Nolin, Valery Lavergne, and Robert S. Hoffman for the EXTRIP group 1948 > 100 guidelines for AKI and CKD 1913 HD invented 1943 HD used for AKI HD used for poisoning 1958 First

More information

Continuous Renal Replacement Therapy. Gregory M. Susla, Pharm.D., F.C.C.M. Associate Director, Medical Information MedImmune, LLC Gaithersburg, MD

Continuous Renal Replacement Therapy. Gregory M. Susla, Pharm.D., F.C.C.M. Associate Director, Medical Information MedImmune, LLC Gaithersburg, MD Continuous Renal Replacement Therapy Gregory M. Susla, Pharm.D., F.C.C.M. Associate Director, Medical Information MedImmune, LLC Gaithersburg, MD 1 Definition of Terms SCUF - Slow Continuous Ultrafiltration

More information

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy Continuous Renal Replacement Therapy Gregory M. Susla, Pharm.D., F.C.C.M. Associate Director, Medical Information MedImmune, LLC Gaithersburg, MD Definition of Terms SCUF - Slow Continuous Ultrafiltration

More information

What is a PET? Although there are many types of pets, we will be discussing the Peritoneal Equilibration Test

What is a PET? Although there are many types of pets, we will be discussing the Peritoneal Equilibration Test 1 2 3 What is a PET? Although there are many types of pets, we will be discussing the Peritoneal Equilibration Test 4 Background information about the PET 1983 Dr. Twardowski and colleagues began measuring

More information

Proceedings of the 36th World Small Animal Veterinary Congress WSAVA

Proceedings of the 36th World Small Animal Veterinary Congress WSAVA www.ivis.org Proceedings of the 36th World Small Animal Veterinary Congress WSAVA Oct. 14-17, 2011 Jeju, Korea Next Congress: Reprinted in IVIS with the permission of WSAVA http://www.ivis.org 14(Fri)

More information

Basics and Decontamination in Clinical Toxicology

Basics and Decontamination in Clinical Toxicology ! Klinikum rechts der Isar Technische Universität München Basics and Decontamination in Clinical Toxicology! Toxi-Latin Porto Alegre 2014 Florian Eyer Toxicological Department 2nd Medizinische Klinik Klinikum

More information

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment. PHA 5127 Second Exam Fall 2012 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Put all answers on the bubble sheet TOTAL /150 pts 1 Question Set I (True or

More information

Recent advances in CRRT

Recent advances in CRRT Recent advances in CRRT JAE IL SHIN, M.D., Ph.D. Department of Pediatrics, Severance Children s Hospital, Yonsei University College of Medicine, Seoul, Korea Pediatric AKI epidemiology and demographics

More information

ICU Volume 11 - Issue 3 - Autumn Series

ICU Volume 11 - Issue 3 - Autumn Series ICU Volume 11 - Issue 3 - Autumn 2011 - Series Impact of Pharmacokinetics of Antibiotics in ICU Clinical Practice Introduction The efficacy of a drug is mainly dependent on its ability to achieve an effective

More information

RENAL FAILURE IN ICU. Jo-Ann Vosloo Department Critical Care SBAH

RENAL FAILURE IN ICU. Jo-Ann Vosloo Department Critical Care SBAH RENAL FAILURE IN ICU Jo-Ann Vosloo Department Critical Care SBAH DEFINITION: RIFLE criteria Criteria for initiation of RRT Modes of RRT (options) CRRT = continuous renal replacement therapy SCUF : Ultra-filtration

More information

CRRT Fundamentals Pre-Test. AKI & CRRT 2017 Practice Based Learning in CRRT

CRRT Fundamentals Pre-Test. AKI & CRRT 2017 Practice Based Learning in CRRT CRRT Fundamentals Pre-Test AKI & CRRT 2017 Practice Based Learning in CRRT Question 1 A 72-year-old man with HTN presents to the ED with slurred speech, headache and weakness after falling at home. He

More information

Levocetirizine dihydrochloride

Levocetirizine dihydrochloride INSERT TEXT UAP Levocetirizine dihydrochloride Allerzet 5 mg Tablet Antihistamine FORMULATION Each film-coated tablet contains: Levocetirizine dihydrochloride.. 5 mg PRODUCT DESCRIPTION Levocetirine 5

More information

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment. PHA 5127 Final Exam Fall 2010 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Please transfer the answers onto the bubble sheet. The question number refers

More information

Salicylate (Aspirin) Ingestion California Poison Control Background 1. The prevalence of aspirin-containing analgesic products makes

Salicylate (Aspirin) Ingestion California Poison Control Background 1. The prevalence of aspirin-containing analgesic products makes Salicylate (Aspirin) Ingestion California Poison Control 1-800-876-4766 Background 1. The prevalence of aspirin-containing analgesic products makes these agents, found in virtually every household, common

More information

Adjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes

Adjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes Adjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes Brian Hardy, PharmD, FCSHP, FCCP Coordinator Education and Clinical Programs Department of Pharmacy Sunnybrook

More information

Drug Use in Dialysis

Drug Use in Dialysis (Last Updated: 08/22/2018) Created by: Socco, Samantha Drug Use in Dialysis Drambarean, B. (2017). Drug Use in Dialysis. Lecture presented at PHAR 503 Lecture in UIC College of Pharmacy, Chicago. DIALYSIS

More information

Drug Dosing in Renal Insufficiency. Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila

Drug Dosing in Renal Insufficiency. Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila Drug Dosing in Renal Insufficiency Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila Declaration of Conflict of Interest For today s lecture on Drug Dosing in Renal

More information

- SLED Sustained Low-Efficiency Dialysis

- SLED Sustained Low-Efficiency Dialysis Continuous Renal Replacement Therapy Gregory M. Susla, Pharm.D., F.C.C.M. Associate Director, Medical Information MedImmune, LLC Gaithersburg, MD 1 Definition of Terms - SCUF - Slow Continuous Ultrafiltration

More information

PD In Acute Kidney Injury. February 7 th -9 th, 2013

PD In Acute Kidney Injury. February 7 th -9 th, 2013 PD In Acute Kidney Injury February 7 th -9 th, 2013 Objectives PD as a viable initial therapy PD in AKI PD versus dhd PD versus CVVHD Why not PD first PD for AKI Early days (1970 s) PD was the option of

More information

PHA 5128 Final Exam Spring 2004 Version A. On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA 5128 Final Exam Spring 2004 Version A. On my honor, I have neither given nor received unauthorized aid in doing this assignment. PHA 5128 Final Exam Spring 2004 Version A On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name There are 18 questions. Total /120 pts Final 2004 1 1. T.P., a 66-year-old,

More information

MTnL Tablet/ MTnL Kid Tablet Montelukast & Levocetirizine dihydrochloride

MTnL Tablet/ MTnL Kid Tablet Montelukast & Levocetirizine dihydrochloride MTnL Tablet/ MTnL Kid Tablet Montelukast & Levocetirizine dihydrochloride COMPOSITION MTnL Tablets Each film-coated tablet contains: Montelukast sodium equivalent to montelukast Levocetirizine dihydrochloride

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS ----------------------------------------------------------------------------------------------------------------- 1. NAME OF THE MEDICINAL PRODUCT Legalon SIL 528.5 mg

More information

PHA Second Exam Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA Second Exam Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment. PHA 5127 Second Exam Fall 2013 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question/Points Set I 20 pts Set II 20 pts Set III 20 pts Set IV 20 pts Set

More information

The Hypotensive Poisoned Patient. Robert S. Hoffman, MD Director, NYC PCC

The Hypotensive Poisoned Patient. Robert S. Hoffman, MD Director, NYC PCC The Hypotensive Poisoned Patient Robert S. Hoffman, MD Director, NYC PCC Some Definitions Hypotension = Low blood pressure Failure of macrocirculation Shock = Poor tissue perfusion Failure of microcirculation

More information

Practical issues - dosing on extracorporeal circuits

Practical issues - dosing on extracorporeal circuits Practical issues - dosing on extracorporeal circuits Jason A Roberts B Pharm (Hons), PhD, FSHP Professor of Medicine and Pharmacy The University of Queensland, Australia Royal Brisbane and Women s Hospital,

More information

Can We Achieve Precision Solute Control with CRRT?

Can We Achieve Precision Solute Control with CRRT? Can We Achieve Precision Solute Control with CRRT? Claudio Ronco, M.D. David Selewski, M.D. Rolando Claure-Del Granado, M.D. AKI & CRRT Conference February, 2019 Disclosures I have no actual or potential

More information

Salicylates commonly cause tinnitus, deafness, nausea and vomiting (salicylism). Hyperventilation results from stimulation of respiratory centre.

Salicylates commonly cause tinnitus, deafness, nausea and vomiting (salicylism). Hyperventilation results from stimulation of respiratory centre. Aspirin poisoning CLINICAL FEATURES Salicylates commonly cause tinnitus, deafness, nausea and vomiting (salicylism). Hyperventilation results from stimulation of respiratory centre. Severe poisoning causes

More information

Composition: Each tablet contain. Levocetirizine. Each 5ml contains. Montelukast. Pharmacokinetic properties:

Composition: Each tablet contain. Levocetirizine. Each 5ml contains. Montelukast. Pharmacokinetic properties: Composition: Each tablet contain Montelukast Levocetirizine 10mg 5mg Each 5ml contains Montelukast Levocetirizine 4mg 2.5mg Pharmacokinetic properties: Peak plasma concentrations of montelukast are achieved

More information

Acute Kidney Injury (AKI) How Wise is Early Dialysis in Critically Ill Patients? Modalities of Dialysis

Acute Kidney Injury (AKI) How Wise is Early Dialysis in Critically Ill Patients? Modalities of Dialysis Acute Kidney Injury (AKI) How Wise is Early Dialysis in Critically Ill Patients? A common condition in ICU patients Associated with high mortality and morbidity Renal Replacement Therapy (RRT) is the cornerstone

More information

Basic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics

Basic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics Basic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics Learning Outcomes Define biopharmaceutics Describe 4 processes of pharmacokinetics Describe factors that affect medication absorption Describe

More information

Name: UFID: PHA Exam 2. Spring 2013

Name: UFID: PHA Exam 2. Spring 2013 PHA 5128 Exam 2 Spring 2013 1 Carbamazepine (5 points) 2 Theophylline (10 points) 3 Gentamicin (10 points) 4 Drug-drug interaction (5 points) 5 Lidocaine (5 points) 6 Cyclosporine (5 points) 7 Phenobarbital

More information

Renal replacement therapy in Pediatric Acute Kidney Injury

Renal replacement therapy in Pediatric Acute Kidney Injury Renal replacement therapy in Pediatric Acute Kidney Injury ASCIM 2014 Dr Adrian Plunkett Consultant Paediatric Intensivist Birmingham Children s Hospital, UK Aims of the presentation Important topic: AKI

More information

C OBJECTIVES. Basic Pharmacokinetics LESSON. After completing Lesson 2, you should be able to:

C OBJECTIVES. Basic Pharmacokinetics LESSON. After completing Lesson 2, you should be able to: LESSON 2 Basic Pharmacokinetics C OBJECTIVES After completing Lesson 2, you should be able to: 1. Define the concept of apparent volume of distribution and use an appropriate mathematical equation to calculate

More information

The general Concepts of Pharmacokinetics

The general Concepts of Pharmacokinetics The general Concepts of Pharmacokinetics What is this jargon? Is it useful? C max, clearance, Vd, half-life, AUC, bioavailability, protein binding F. Van Bambeke, E. Ampe, P.M. Tulkens (Université catholique

More information

CRRT Interactive Hyperkalemia Cases AKI & CRRT conference 2018

CRRT Interactive Hyperkalemia Cases AKI & CRRT conference 2018 CRRT Interactive Hyperkalemia Cases AKI & CRRT conference 2018 Case 1 Potassium Clearance A 70 kg male is placed on CVVH with a total ultrafiltration rate (effluent rate) of 20 ml/kg/hr. The Blood Flow

More information

CRRT Interactive Hyperkalemia Cases AKI & CRRT conference 2018

CRRT Interactive Hyperkalemia Cases AKI & CRRT conference 2018 CRRT Interactive Hyperkalemia Cases AKI & CRRT conference 2018 Case 1 Potassium Clearance A 70 kg male is placed on CVVH with a total ultrafiltration rate (effluent rate) of 20 ml/kg/hr. The Blood Flow

More information

Drug dosing in patients with acute kidney injury

Drug dosing in patients with acute kidney injury Drug dosing in patients with acute kidney injury They don t know what they are doing Jan Jan T. T. Kielstein Department of of Nephrology and and Hypertension Medical School School Hannover Drug dosing

More information

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment. PHA 5127 Second Exam Fall 2011 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Put all answers on the bubble sheet TOTAL /200 pts 1 Question Set I (True or

More information

Neither activated charcoal nor whole bowel irrigation (WBI) is indicated in the routine management of acute or chronic lithium toxicity.

Neither activated charcoal nor whole bowel irrigation (WBI) is indicated in the routine management of acute or chronic lithium toxicity. CRACKCast E160 Lithium Key concepts; The clinical pattern of acute and chronic toxicity is different. Gastrointestinal symptoms occur early and neurological toxicity manifest late in acute toxicity. Neurological

More information

Ch 19: The Kidneys. Functional unit of kidneys:?? Developed by John Gallagher, MS, DVM

Ch 19: The Kidneys. Functional unit of kidneys:?? Developed by John Gallagher, MS, DVM Ch 19: The Kidneys Homeostatic regulation of ECF volume and BP Osmolarity 290 mosm Ion balance Na+ and K+, etc. ph (acid-base balance Excretion of wastes & foreign substances Hormone production EPO Renin

More information

Basic Concepts of TDM

Basic Concepts of TDM TDM Lecture 1 5 th stage What is TDM? Basic Concepts of TDM Therapeutic drug monitoring (TDM) is a branch of clinical pharmacology that specializes in the measurement of medication concentrations in blood.

More information

Dialysis Dose Prescription and Delivery. William Clark, M.D. Claudio Ronco, M.D. Rolando Claure-Del Granado, M.D. CRRT Conference February 15, 2012

Dialysis Dose Prescription and Delivery. William Clark, M.D. Claudio Ronco, M.D. Rolando Claure-Del Granado, M.D. CRRT Conference February 15, 2012 Dialysis Dose Prescription and Delivery William Clark, M.D. Claudio Ronco, M.D. Rolando Claure-Del Granado, M.D. CRRT Conference February 15, 2012 Dose in RRT: Key concepts Dose definition Quantifying

More information

Can We Achieve Precision Solute Control with CRRT?

Can We Achieve Precision Solute Control with CRRT? Can We Achieve Precision Solute Control with CRRT? Claudio Ronco, M.D. David Selewski, M.D. Rolando Claure-Del Granado, M.D. AKI & CRRT Conference February, 2019 Disclosures I have no actual or potential

More information

CRRT Fundamentals Pre- and Post- Test. AKI & CRRT Conference 2018

CRRT Fundamentals Pre- and Post- Test. AKI & CRRT Conference 2018 CRRT Fundamentals Pre- and Post- Test AKI & CRRT Conference 2018 Question 1 Which ONE of the following statements regarding solute clearance in CRRT is MOST correct? A. Convective and diffusive solute

More information

Atypical Dialysis Circumstances Pregnancy- Drug Overdose

Atypical Dialysis Circumstances Pregnancy- Drug Overdose Atypical Dialysis Circumstances Pregnancy- Drug Overdose Emad Magdy Shawky Hemodialysis Course, 11 th OCT. 2016 10 TIPS To Approach A Pregnant Lady On Hemodialysis 1 CHANCE Hormonal changes (Estrogen-

More information

CRRT and Drug dosing. Karlee Johnston Lead Pharmacist Division of Critical Care ICU Education June 2017

CRRT and Drug dosing. Karlee Johnston Lead Pharmacist Division of Critical Care ICU Education June 2017 CRRT and Drug dosing Karlee Johnston Lead Pharmacist Division of Critical Care ICU Education June 2017 This talk In scope CRRT modalities with regard to medicine Principles of drugs with regard to dialysis

More information

SHC Vancomycin Dosing Guide

SHC Vancomycin Dosing Guide SHC Vancomycin Dosing Guide A: Initial dosing considerations B. Pharmacodynamic Targets: goal AUC and troughs C. Loading dose D: Initial Vancomycin Maintenance Dosing and Serum Concentration Monitoring

More information

ECMO & Renal Failure Epidemeology Renal failure & effect on out come

ECMO & Renal Failure Epidemeology Renal failure & effect on out come ECMO Induced Renal Issues Transient renal dysfunction Improvement in renal function ECMO & Renal Failure Epidemeology Renal failure & effect on out come With or Without RRT Renal replacement Therapy Utilizes

More information

Clinical Pathway: Management Of The Life-Threatening Overdose

Clinical Pathway: Management Of The Life-Threatening Overdose Clinical Pathway: Management Of The Life-Threatening Overdose Intravenous access Oxygen Pulse oximetry n-invasive blood pressure monitoring Accu-Check ECG monitoring and ECG Chest x-ray Respiratory depression?

More information

Renal Replacement Therapy in ICU. Dr. Sunil Sharma Senior Resident Dept of Pulmonary Medicine

Renal Replacement Therapy in ICU. Dr. Sunil Sharma Senior Resident Dept of Pulmonary Medicine Renal Replacement Therapy in ICU Dr. Sunil Sharma Senior Resident Dept of Pulmonary Medicine Introduction Need for RRT in patients with ARF is a common & increasing problem in ICUs Leading cause of ARF

More information

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment. PHA 5127 Final Exam Fall 2012 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Please transfer the answers onto the bubble sheet. The question number refers

More information

PHA First Exam. Fall 2004

PHA First Exam. Fall 2004 PHA 5127 First Exam Fall 2004 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Put all answers on the bubble sheet. If you need to comment or question a problem

More information

PHA Final Exam Fall 2001

PHA Final Exam Fall 2001 PHA 5127 Final Exam Fall 2001 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question/Points 1. /12 pts 2. /8 pts 3. /12 pts 4. /20 pts 5. /27 pts 6. /15

More information

Pharmacokinetics Overview

Pharmacokinetics Overview Pharmacokinetics Overview Disclaimer: This handout and the associated lectures are intended as a very superficial overview of pharmacokinetics. Summary of Important Terms and Concepts - Absorption, peak

More information

PHA Final Exam Fall 2006

PHA Final Exam Fall 2006 PHA 5127 Final Exam Fall 2006 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Please transfer the answers onto the bubble sheet. The question number refers

More information

POISONING AND DRUG OVERDOSAGE

POISONING AND DRUG OVERDOSAGE POISONING AND DRUG OVERDOSAGE Department of Internal Medicine WAN Weiguo General Info All chemicals have potential to be poisons if given a large enough dose Poisoning occurs when exposure to a substance

More information

. Although there is a little

. Although there is a little PHA 58 Spring 007 Case study 4. Baby girl A, 3kg, 5 days, is receiving phenobarbital because of neonatal seizures. An IV loading dose of phenobarbital sodium of 0mg/kg was given followed by maintenance

More information

Cetirizine Proposed Core Safety Profile

Cetirizine Proposed Core Safety Profile Cetirizine Proposed Core Safety Profile Posology and method of administration Elderly subjects: data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function

More information

Chapter 143 Acetaminophen

Chapter 143 Acetaminophen Chapter 143 Acetaminophen Episode overview 1) Describe the metabolism of Acetaminophen 2) Describe the 4 stages of Acetaminophen toxicity 3) List 4 mechanism of action of N-acetylcysteine 4) When do you

More information

PHENYTOIN DOSING INFORMATION. Adult Dosage

PHENYTOIN DOSING INFORMATION. Adult Dosage PHENYTOIN DRUGDEX Evaluations DOSING INFORMATION Adult Dosage Normal Dosage Important Note ) Due to the risk of severe hypotension and cardiac arrhythmias, the rate of IV phenytoin administration should

More information

CRRT for the Experience User 1. Claudio Ronco, M.D. David Selewski, M.D. Rolando Claure-Del Granado, M.D. AKI & CRRT Conference March, 2018

CRRT for the Experience User 1. Claudio Ronco, M.D. David Selewski, M.D. Rolando Claure-Del Granado, M.D. AKI & CRRT Conference March, 2018 CRRT for the Experience User 1 Claudio Ronco, M.D. David Selewski, M.D. Rolando Claure-Del Granado, M.D. AKI & CRRT Conference March, 2018 Disclosures I have no actual or potential conflict of interest

More information

CRRT. ICU Fellowship Training Radboudumc

CRRT. ICU Fellowship Training Radboudumc CRRT ICU Fellowship Training Radboudumc Timing RRT Consider the following: Underlying cause and reversibility. Rapid improvement unlikely with high dose vasopressors and continuous exposure to other risk

More information

Acute Kidney Injury. Eleanor Haskey BSc(hons) RVN VTS(ECC) VPAC A1

Acute Kidney Injury. Eleanor Haskey BSc(hons) RVN VTS(ECC) VPAC A1 Acute Kidney Injury Eleanor Haskey BSc(hons) RVN VTS(ECC) VPAC A1 Anatomy and Physiology The role of the kidneys is to filter the blood through the glomerulus to form filtrate. The filtrate is then reabsorbed

More information

PHA Spring First Exam. 8 Aminoglycosides (5 points)

PHA Spring First Exam. 8 Aminoglycosides (5 points) PHA 5128 Spring 2012 First Exam 1 Aminoglycosides (5 points) 2 Aminoglycosides (10 points) 3 Basic Principles (5 points) 4 Basic Principles (5 points) 5 Bioavailability (5 points) 6 Vancomycin (5 points)

More information

Acute Kidney Injury- What Is It and How Do I Treat It?

Acute Kidney Injury- What Is It and How Do I Treat It? Acute Kidney Injury- What Is It and How Do I Treat It? Jayant Kumar, MD Renal Medicine Assoc., Albuquerque, NM Incidence of ARF in ICU Causes of ARF Non -ICU ICU 1 KDIGO criteria for AKI Increase in serum

More information

Pharmacokinetics Applied to the Treatment of Asthma

Pharmacokinetics Applied to the Treatment of Asthma Pharmacokinetics Applied to the Treatment of Asthma 2016 edition by David C. McMillan, PhD Department of Pharmacology and Experimental Neuroscience College of Medicine University of Nebraska Medical Center

More information

BASIC PHARMACOKINETICS

BASIC PHARMACOKINETICS BASIC PHARMACOKINETICS MOHSEN A. HEDAYA CRC Press Taylor & Francis Croup Boca Raton London New York CRC Press is an imprint of the Taylor & Francis Group, an informa business Table of Contents Chapter

More information

LD = (Vd x Cp)/F (Vd x Cp)/F MD = (Css x CL x T)/F DR = (Css x (Vm-DR))/Km Css = (F x D)/(CL x T) (Km x DR)/(Vm DR)

LD = (Vd x Cp)/F (Vd x Cp)/F MD = (Css x CL x T)/F DR = (Css x (Vm-DR))/Km Css = (F x D)/(CL x T) (Km x DR)/(Vm DR) PHARMKIN WORKSHOP A PHARMACOKINETICS TEACHING SIMULATION Joseph K. Ritter, Ph.D. Associate Professor, Pharmacology and Toxicology MSB 536, 828-1022, jritter@mail2.vcu.edu Tompkins-McCaw Libray Room 2-006

More information

Chapter 2 End-Stage Renal Disease: Scope and Trends

Chapter 2 End-Stage Renal Disease: Scope and Trends Chapter 2 End-Stage Renal Disease: Scope and Trends Chapter 2 End-Stage Renal Disease: Scope and Trends END-STAGE RENAL DISEASE DEFINED The primary functions of the kidney are to remove waste products

More information

Lippincott Questions Pharmacology

Lippincott Questions Pharmacology Lippincott Questions Pharmacology Edition Two: Chapter One: 1.Which one of the following statements is CORRECT? A. Weak bases are absorbed efficiently across the epithelial cells of the stomach. B. Coadministration

More information

Renal Impairment From Dettli to Guideline: What can we learn?

Renal Impairment From Dettli to Guideline: What can we learn? Renal Impairment From Dettli to Guideline: What can we learn? SocraMetrics GmbH Mainzerhofplatz 14 99084 Erfurt phone: ++49-361-6020526 fax: ++49-361-6020525 e-mail: meinolf.wonnemann@socrametrics.de SocraMetrics

More information

Blood purification in sepsis

Blood purification in sepsis Blood purification in sepsis Joannes-Boyau O Dept of anesthesiology and intensive care, University Hospital of Bordeaux, France 1 Types of Blood Purification hemofilters regular pore size (MW < 40,000D)

More information

REVISITING THE PHARMACOKINETICS IN PATIENTS

REVISITING THE PHARMACOKINETICS IN PATIENTS REVISITING THE PHARMACOKINETICS IN PATIENTS WITH IMPAIRED RENAL FUNCTION IN THE LIGHT OF THE LATEST FDA AND EMA GUIDELINES 3 RD CONFERENCE OF EUROPEAN PHARMACOLOGICAL SOCIETIES EUROPEAN COMPETITIVENESS

More information

PHA 5128 Spring 2000 Final Exam

PHA 5128 Spring 2000 Final Exam PHA 128 Spring 2000 Final Exam On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name TYPED KEY Questions Points 1. /1 2. /1 3. /1 4. /1. /10 6. /10. /10 8. /10

More information

CSI (Clinical Scenario Investigation): Hyperkalemia

CSI (Clinical Scenario Investigation): Hyperkalemia CSI (Clinical Scenario Investigation): Hyperkalemia Alison Thomas, RN(EC), MN, CNeph(C) Ann Jones, RN(EC), MSN, CNeph(C) Joyce Hunter, RN, Vascular Access Co-ordinator Simcoe Muskoka Regional Kidney Care

More information

Saião A, Chan B, Isbister GK Department of Clinical Toxicology and Pharmacology, Calvary Mater Newcastle, NSW Emergency Department, Prince of Wales

Saião A, Chan B, Isbister GK Department of Clinical Toxicology and Pharmacology, Calvary Mater Newcastle, NSW Emergency Department, Prince of Wales Saião A, Chan B, Isbister GK Department of Clinical Toxicology and Pharmacology, Calvary Mater Newcastle, NSW Emergency Department, Prince of Wales Hospital, Sydney, NSW, Australia Paracetamol Poisoning

More information

It the process by which a drug reversibly leaves blood and enter interstitium (extracellular fluid) and/ or cells of tissues.

It the process by which a drug reversibly leaves blood and enter interstitium (extracellular fluid) and/ or cells of tissues. It the process by which a drug reversibly leaves blood and enter interstitium (extracellular fluid) and/ or cells of tissues. Primarily depends on: 1.Regional blood flow. 2.Capillary permeability. 3.Protein

More information

PHA 5127 FINAL EXAM FALL On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA 5127 FINAL EXAM FALL On my honor, I have neither given nor received unauthorized aid in doing this assignment. PHA 5127 FINAL EXAM FALL 1997 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question Points 1. /14 pts 2. /10 pts 3. /8 pts 4 /8 pts 5. /12 pts 6. /8 pts

More information

Pharmacokinetics One- compartment Open Model Lec:2

Pharmacokinetics One- compartment Open Model Lec:2 22 Pharmacokinetics One- compartment Open Model Lec:2 Ali Y Ali BSc Pharmacy MSc Industrial Pharmaceutical Sciences Dept. of Pharmaceutics School of Pharmacy University of Sulaimani 1 Outline Introduction

More information

Excretory System Workbook

Excretory System Workbook Excretory System Workbook MCHS Biology 20 Mr. Korotash Name: Date: 1 Study the diagram above. Name the structures and indicate their functions by completing the following table: Structure 1. Function 2.

More information

Ch 17 Physiology of the Kidneys

Ch 17 Physiology of the Kidneys Ch 17 Physiology of the Kidneys Review Anatomy on your own SLOs List and describe the 4 major functions of the kidneys. List and explain the 4 processes of the urinary system. Diagram the filtration barriers

More information

HEMODIAFILTRATION PRINCIPLES AND ADVANTAGES OVER CONVENTIONAL HD PRESENTATION BY DR.ALI TAYEBI

HEMODIAFILTRATION PRINCIPLES AND ADVANTAGES OVER CONVENTIONAL HD PRESENTATION BY DR.ALI TAYEBI HEMODIAFILTRATION PRINCIPLES AND ADVANTAGES OVER CONVENTIONAL HD PRESENTATION BY DR.ALI TAYEBI high-flux Hemodiafiltration (HDF) Combination of two dialysis techniques, hemodialysis and hemofiltration:

More information

End-Stage Renal Disease. Anna Vinnikova, M.D. Associate Professor of Medicine Division of Nephrology

End-Stage Renal Disease. Anna Vinnikova, M.D. Associate Professor of Medicine Division of Nephrology End-Stage Renal Disease Anna Vinnikova, M.D. Associate Professor of Medicine Division of Nephrology ESRD : Life with renal replacement therapy CASE: 18 month old male with HUS develops ESRD PD complicated

More information

CLINICAL PHARMACOKINETICS INDEPENDENT LEARNING MODULE

CLINICAL PHARMACOKINETICS INDEPENDENT LEARNING MODULE CLINICAL PHARMACOKINETICS INDEPENDENT LEARNING MODULE Joseph K. Ritter, Ph.D. Assoc. Professor, Pharmacology and Toxicology MSB 536, 828-1022, jritter@vcu.edu This self study module will reinforce the

More information

How effective is chelation? contrasts in iron and digoxin poisoning. Nick Bateman Edinburgh

How effective is chelation? contrasts in iron and digoxin poisoning. Nick Bateman Edinburgh How effective is chelation? contrasts in iron and digoxin poisoning Nick Bateman Edinburgh Chelation Chemical chelating agents chemical that bind metal ions and other toxic groups e.g. desferrioxamine

More information

PHARMACOKINETICS SMALL GROUP II:

PHARMACOKINETICS SMALL GROUP II: PHARMACOKINETICS SMALL GROUP II: Question 1 Why are some drug therapies initiated with a loading dose? Emphasize that LD establishes initial therapeutic level quickly. The time to reach the steady-state

More information

Renal replacement therapy in acute kidney injury

Renal replacement therapy in acute kidney injury 6 February 2009 CONTENTS Renal replacement therapy in acute kidney injury S Jithoo Commentator: CL Quantock Moderator: LW Drummond INTRODUCTION... 3 WHAT IS RENAL REPLACEMENT THERAPY?... 3 MODES OF RENAL

More information

pharmacy, we need to see how clinical pharmacokinetics fits into the pharmaceutical care process.

pharmacy, we need to see how clinical pharmacokinetics fits into the pharmaceutical care process. Therapeutic drug monitoring (TDM) Is a tool that can guide the clinician to provide effective and safe drug therapy in the individual patient. Monitoring can be used to confirm a plasma drug concentration

More information

egfr 34 ml/min egfr 130 ml/min Am J Kidney Dis 2002;39(suppl 1):S17-S31

egfr 34 ml/min egfr 130 ml/min Am J Kidney Dis 2002;39(suppl 1):S17-S31 Update on Renal Therapeutics Caroline Ashley Lead Pharmacist Renal Services UCL Centre for Nephrology, Royal Free Hospital, London Kongress für Arzneimittelinformation January 2011 What are we going to

More information

Dimaval (DMPS) 100 mg Hartkapseln

Dimaval (DMPS) 100 mg Hartkapseln SUMMARY OF PRODUCT CHARACTERISTICS Dimaval (DMPS) 100 mg Hartkapseln 1. NAME OF THE MEDICINAL PRODUCT Dimaval (DMPS) 100 mg Hartkapseln 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 hard capsule contains

More information

Methotrexate: is acute oral overdose ever a concern?

Methotrexate: is acute oral overdose ever a concern? Methotrexate: is acute oral overdose ever a concern? Dr Betty Chan Emergency Physician & Clinical Toxicologist Prince of Wales Hospital New South Wales Poisons Information Centre Case Study 1 53F(80kg)

More information